SkinBioTherapeutics PLC

By Financial Journalist: Elric Langton | 3 August 2026

Mike, Alex, and I all have a financial interest in SkinBioTherapeutics.

I had not intended to return to SkinBioTherapeutics quite so quickly. However, a recent article questioning whether the Company’s cash will “last long enough” appears to have caused some anxiety among some investors, while some commentators/investors appear to be asserting their own assumptions as established facts.

Some now seem convinced that SkinBioTherapeutics will require another equity raise, probably at a punishing discount.

That is a serious conclusion. It is also one that appears to fly directly in the face of the Company’s own published statements.

Let’s have some fun.

The article appears to convert a cash-management risk into an implied near-term cash crisis without sufficient evidence.

Its central analytical weaknesses are:

1. extrapolating a distorted five-month cash movement;

2. failing to adjust adequately for approximately £700k of investigation expenditure;

3. conflating operating losses with cash burn;

4. overlooking that the major disclosed loss sat within Corporate;

5. failing to engage properly with the 12-month going-concern assessment;

6. assuming that £1.5 million inevitably leads to an equity raise;

7. treating the current cost base as though all expenditure were recurring.

Given the damage caused by the governance and accounting failures associated with former CEO Stuart Ashman, the present Board knows it cannot afford careless language. Its immediate task is to restore credibility with shareholders.

BTW, my right eye now squints whenever I mention Ashman by name—are there any lawyers in the house?

Against that background, investors should distinguish between legitimate caution over a £1.5m cash balance and an assertion that a discounted fundraising is inevitable.

The going-concern statement matters

SkinBioTherapeutics reported cash of £1.5m as of May 2026 and stated plainly that careful management of resources is essential. To be expected, right.

Nobody should attempt to dress £1.5m up as a fortress balance sheet. I’m not attempting to.

However, the directors also reviewed the Group’s budget, cash resources and financial obligations and concluded that SkinBioTherapeutics had adequate resources to continue operating for at least 12 months. The Company subsequently reiterated that its FY26 accounts would be prepared on a going-concern basis.

That statement does not guarantee the Company will never raise capital. No responsible investor should interpret it that way.

The usual caveats apply.

A Company may eventually raise money for expansion, an acquisition (HOPEFULLY NOT) or an accelerated commercial opportunity. Circumstances may also change.

But that is materially different from claiming that SkinBioTherapeutics must raise cash before the year-end merely to remain solvent.

Anyone making that assertion must explain why the Board’s formal cash-flow assessment should be discounted or ignored.

That burden is particularly important now. The directors are attempting to rebuild trust after a deeply damaging period. Publishing a going-concern assessment that could unravel within months would destroy what little credibility remains.

Additionally, separate from anything said in the Business News Post, is additional scaremongering about the board's exorbitant remuneration packages, even before they are known. Obsician offers a very reasonable view on this; you can read here.

It would be an extraordinary risk for the new leadership to take.

Cash movement is not recurring cash burn